Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter

被引:99
作者
Fujisawa, H
Kurrer, M
Reis, RM
Yonekawa, Y
Kleihues, P
Ohgaki, H
机构
[1] Int Agcy Res Canc, Unit Mol Pathol, F-69372 Lyon 08, France
[2] Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland
[3] Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland
关键词
D O I
10.1016/S0002-9440(10)65135-8
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Loss of heterozygosity on chromosome 10 (LOH#10) is the most frequent genetic alteration in glioblastomas and occurs in more than 80% of cases. We recently reported that PTEN (MMAC1) on 10q23.3 is mutated in approximately 30% of primary (de novo) glioblastomas but rarely in secondary glioblastomas that progressed from low-grade or anaplastic astrocytomas, Because secondary glioblastomas also show LOH#10, tumor suppressor genes other than PTEN are likely to be involved. We analyzed LOH on chromosomes 10 and 19, using polymorphic microsatellite markers in microdissected foci showing histologically an abrupt transition from low-grade or anaplastic astrocytoma to glioblastoma, suggestive of the emergence of a new tumor clone. When compared to the respective low-grade or anaplastic astrocytoma of the same biopsy, deletions were detected in 7 of 8 glioblastoma foci on 10q25-qter distal to D10S597, covering the DMBT1 and FGFR2 loci. Six of 8 foci showed LOH at one or two flanking markers of PTEN but did not contain PTEN mutations. LOH on 10p and 19q was found in only one case each. These data indicate that acquisition of a highly anaplastic glioblastoma phenotype with marked proliferative activity and lack of glial fibrillary acidic protein expression is associated with loss of a putative tumor suppressor gene on 10q25-qter.
引用
收藏
页码:387 / 394
页数:8
相关论文
共 57 条
  • [1] Albarosa R, 1996, AM J HUM GENET, V58, P1260
  • [2] Boström J, 1998, CANCER RES, V58, P29
  • [3] Burger PC, 1994, TUMORS CENTRAL NERVO
  • [4] Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers
    Cairns, P
    Evron, E
    Okami, K
    Halachmi, N
    Esteller, M
    Herman, JG
    Bose, S
    Wang, SI
    Parsons, R
    Sidransky, D
    [J]. ONCOGENE, 1998, 16 (24) : 3215 - 3218
  • [5] Cairns P, 1997, CANCER RES, V57, P4997
  • [6] PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas
    Chiariello, E
    Roz, L
    Albarosa, R
    Magnani, I
    Finocchiaro, G
    [J]. ONCOGENE, 1998, 16 (04) : 541 - 545
  • [7] A metric map of humans: 23,500 loci in 850 bands
    Collins, A
    Frezal, J
    Teague, J
    Morton, NE
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (25) : 14771 - 14775
  • [8] Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas
    deMedina, SGD
    Chopin, D
    ElMarjou, A
    Delouvee, A
    LaRochelle, WJ
    Hoznek, A
    Abbou, C
    Aaronson, SA
    Thiery, JP
    Radvanyi, F
    [J]. ONCOGENE, 1997, 14 (03) : 323 - 330
  • [9] PTEN mutations in gliomas and glioneuronal tumors
    Duerr, EM
    Rollbrocker, B
    Hayashi, Y
    Peters, N
    Meyer-Puttlitz, B
    Louis, DN
    Schramm, J
    Wiestler, OD
    Parsons, R
    Eng, C
    von Deimling, A
    [J]. ONCOGENE, 1998, 16 (17) : 2259 - 2264
  • [10] FULTS D, 1992, CANCER RES, V52, P674